



Global access to HCV – an overview

Charles Gore



This is **hepatitis...**



Access – what this means

- Access to testing
- Access to assessment
- Access to prescribers
- Access to monitoring
- Regulatory approval/licensing in place
- Quality assurance
- Distribution
- Price

This is **hepatitis...**



Access – priority 1

Political will



1. Argentina
2. Australia
3. Canada
4. DPRK
5. Egypt
6. France
7. Indonesia
8. Ireland
9. Japan
10. Kyrgyzstan
11. Lebanon
12. Moldova
13. Mongolia
14. New Zealand
15. UK
16. USA
17. Uzbekistan



- 47 countries say they have a plan; 17 actually have a proper plan
- How many countries will support EB134.R18?

This is **hepatitis...**



Access – priority 2

Support from global funders

- WHA67/EB134.R18
(OP) 3. CALLS upon all relevant United Nations funds, programmes, specialized agencies and other stakeholders:
 - (1) to include prevention, diagnosis and treatment of viral hepatitis in their respective work programmes and work in close collaboration;
 - (2) to identify and disseminate mechanisms to assist countries in the provision of sustainable funding for prevention, diagnosis and treatment of viral hepatitis.
- Lack of appetite will only be changed through political will by MS



Access – priority 3

Affordable diagnostics and drugs

- Differential pricing
- Licence agreements to generic manufacturers
- Medicines Patent Pool
- Local manufacturing in patent-free countries (freedom to operate)
- Patent opposition and local manufacturing
- Compulsory licensing

This is **hepatitis...**



www.worldhepatitisalliance.org

Thank you

This is **hepatitis...**

